Project Grant R03HL172987
Award Date
7/15/24
Completion Date
7/31/26
Dollars Obligated
$114K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Gainesville, FL 32611, USA
Similar Awards
This federal Project Grant award of $246,776.00 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) aims to develop novel methods for creating and validating polygenic scores (PS) that can predict medication response in African American populations. The goal is to create ancestry-robust PS tools that account for local genetic ancestry context, improving their predictive performance for non-European populations. The...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $299,604 to Case Western Reserve University to develop and validate a novel transfer volume regression model. This model aims to enable quantitative clinical risk predictions for major cardiovascular events, including stroke, heart attack, heart failure, and death. The project will leverage commonly used, low-cost screening programs to...
This Project Grant award from the National Heart Lung and Blood Institute (NHLBI), under the Cardiovascular Diseases Research Federal Grant Program (CFDA 93.837), provides $169,222 to the University of Alabama at Birmingham (UAB) to conduct research on ancestry and sex-related pharmacogenomic and metabolomic signatures that influence the response to oral anticoagulant (OAC) medications. The key objectives of this research project are to: 1) Evaluate pharmacogenomic predictors of direct oral...
This Project Grant awarded by the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $392,037 to New York University School of Medicine to conduct a pilot randomized controlled trial to evaluate the feasibility of a biomarker-based precision care approach using a low-dose direct oral anticoagulant and high-intensity statin therapy to improve cardiovascular outcomes in patients with myocardial injury after non-cardiac surgery (MINS). The project aims...
The National Heart, Lung, and Blood Institute (NHLBI), a division of the National Institutes of Health (NIH), awarded a $874,792 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Vanderbilt University Medical Center (VUMC). The award, effective July 15, 2024 through June 30, 2028, will support research to: (1) identify new genetic variants associated with residual atherosclerotic cardiovascular disease (ASCVD) risk in patients on treatment to lower LDL-cholesterol...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) will provide $171,450.00 to investigate the biological mechanisms linking excess body fat (adiposity) and elevated blood lipid levels, and their combined impact on cardiovascular disease risk. The research, led by Dr. Dron, a computational geneticist, aims to: 1) measure how adiposity interacts with genetic variants to influence lipid levels, 2)...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $1,602,792 to the University of North Carolina at Chapel Hill to study the phenotypic consequences of lipoprotein(a) in diverse populations. The research aims to address critical gaps in understanding the impact of lipoprotein(a), a major cardiovascular disease risk factor, across different ancestral groups. Key objectives include assembling a large, ancestrally...
The University of Pittsburgh was awarded a $705,915 Project Grant from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to conduct the "Integrative Model of Metabolomics, Equol and Atherosclerotic Cardiovascular Disease (IMMEA)" study. The study aims to (1) determine the association of equol-producing status with atherosclerotic cardiovascular disease (ASCVD) and (2) build predictive models of ASCVD from equol, marine omega-3 fatty acids,...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $487,567 to Indiana University to conduct integrative genomic analysis and develop high-dimensional risk prediction models for congenital heart defects (CHDs). The research aims to identify genetic variants and biological pathways associated with CHDs, as well as build predictive models leveraging genetic, epigenetic,...
This federal Project Grant award, totaling $753,813 and provided by the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research), supports research to develop novel machine learning techniques for predicting cardiovascular outcomes in patients with clonal hematopoiesis of indeterminate potential (CHIP). The key goals are to use cardiac MRI imaging and genomic data to: 1) Develop a machine learning model to accurately identify CHIP patients and predict their risk...